-
1986：
Founded by Wei-Cheng WANG, the current president of EB Pharma
-
1990：
Acquired the distribution right of Zatiden for Northern Taiwan from Sandoz
-
1993：
Acquired the distribution right of Voltaren for Northern Taiwan from Ciba-Geigy
-
1996：
With the merger of Sandoz and Ciba-Geigy into Novartis, EB Pharma became the largest distributor of Novartis in Taiwan, marketing more products such as Parlodel, Clozaril, Etumine, and Hydergine
-
2003：
Started to develop own branded generic products in Taiwan
-
2004：
First own branded generic Meto 250mg (Metformin) launched
-
2005：
Suride 200mg (Sulpiride) launched
-
2007：
Epram 10mg (Escitalopram) and Pane 40mg IV (Pantoprazole) launched
-
2009：
Fute 0.5/5mg (Flupentixol) launched as EB's first specialty generic products
-
2011：
Epine 25/200/300mg (Quetiapine) launched
-
2014：
Ritalin (partial channels), Ritalin LA (partial channels), Cibacen, Nitroderm TTS were added to our Novartis portfolio
-
2016：
Annual sales reached NT$ 300 million，Trileptal, Tegretol, Exelon (partial channels), Comtan (partial channels)、Stalevo (partial channels) were added to our Novartis portfolio
-
2018：
Ritalin IR and Ritalin LA marketing right of all remaining channels were added to our Novartis portfolio
-
2022：
Ezole 2/5mg (Aripiprazole) launched; Exprexa 5/10mg (Olanzapine) launched; Exprexa 10mg Lyophilized Injection (Olanzapine) launched；Exelon marketing right of all remaining channels were added to our Novartis portfolio
-
2023：
Annual sales reached NT$ 900 million; Gilenya and Mayzent marketing right of all channels were added to our Novartis portfolio
